HDAC1 and neoplasm: We next assessed whether HDAC1 inhibition could switch the immune phenotype in the TME from an immune-refractory to an immune-stimulatory feature by reinvigorating the antitumor immunity cycle in NANOGhi-refractory tumor cells.